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Abstract
Introduction Oestrogen receptor α, which mediates the effect
of oestrogen in target tissues, is genetically polymorphic.
Because breast cancer development is dependent on
oestrogenic influence, we have investigated whether
polymorphisms in the oestrogen receptor α gene (ESR1) are
associated with breast cancer risk.
Methods We genotyped breast cancer cases and age-matched
population controls for one microsatellite marker and four single-
nucleotide polymorphisms (SNPs) in ESR1. The numbers of
genotyped cases and controls for each marker were as follows:
TAn, 1514 cases and 1514 controls; c.454-397C → T, 1557
cases and 1512 controls; c.454-351A → G, 1556 cases and
1512 controls; c.729C → T, 1562 cases and 1513 controls;
c.975C → G, 1562 cases and 1513 controls. Using logistic
regression models, we calculated odds ratios (ORs) and 95%
confidence intervals (CIs). Haplotype effects were estimated in
an exploratory analysis, using expectation-maximisation
algorithms for case-control study data.
Results There were no compelling associations between single
polymorphic loci and breast cancer risk. In haplotype analyses,
a common haplotype of the c.454-351A → G or c.454-397C →
T and c.975C → G SNPs appeared to be associated with an
increased risk for ductal breast cancer: one copy of the c.454-
351A → G and c.975C → G haplotype entailed an OR of 1.19
(95% CI 1.06–1.33) and two copies with an OR of 1.42 (95%
CI 1.15–1.77), compared with no copies, under a model of
multiplicative penetrance. The association with the c.454-397C
→ T and c.975C → G haplotypes was similar. Our data
indicated that these haplotypes were more influential in women
with a high body mass index. Adjustment for multiple
comparisons rendered the associations statistically non-
significant.
Conclusion We found suggestions of an association between
common haplotypes in ESR1  and the risk for ductal breast
cancer that is stronger in heavy women.
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Introduction
Oestrogenic stimulation is central in breast carcinogenesis
and oestrogen receptor α is the most important mediator of
the response to stimulation by oestrogens in classical tar-
get tissues, such as the breast epithelium. There are sev-
eral genetic variants of the oestrogen receptor α gene
(ESR1), many of which have been studied in relation to
breast cancer. Linkage was first described between an
intron 1 variant (c.454-351A → G) and breast cancer in a
family with late-onset cases [1]. However, later case-con-
trol studies have not found any convincing evidence for an
association between ESR1 variants and breast cancer risk
BMD = bone mineral density; BMI = body mass index; CI = confidence interval; EM = expectation-maximisation; ESR1 = oestrogen receptor α gene; 
FPRP = false positive report probability; HWE = Hardy–Weinberg equilibrium; OR = odds ratio; PCR = polymerase chain reaction; SNP = single-
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Table 1
Previously published studies about oestrogen receptor α gene polymorphisms and breast cancer
Reference Type of study Polymorphism Study size Population Main effect on risk Other results
Zuppan [1] Linkage analysis c.454-351A→G 11 families American late-onset 
familial cases
N/A Nothing overall, 
linkage in one 
family
Hill [46] Tumor and normal 
samples
c.454-397C→T 188 tumors, 53 
reference 
samples
Not specified N/A c.454-397C→T C 
allele associated 
with ER-
Parl [47] Cases only c.454-397C→T, 
c.454-351A→G
59 cases 56 'American-
white', 3 African-
American, 33–87 
years
N/A c.454-397C→T TT 
were younger at 
diagnosis (more 
often poorly 
differentiated)
Yaich [13] Cases only (case-
control)
c.454-397C→T 257/140 American pre- and 
postmenopausal
None c.454-397C→T TT 
were younger at 
diagnosis (slightly 
more often ER-)
Andersen [41] Case-control c.454-397C→T 360/672 Norwegian 
Caucasian, pre- 
and 
postmenopausal 
(27–94 years)
c.454-351A→G: 
increased risk 
with G allele
c.454-351A→G G 
were older at 
diagnosis, P = 
0.25
c.454-351A→G c.454-397C→T: 
None
c.454-397C→T T 
more often PR-
Roodi [11] Cases only c.975C→G, 
c.729C→T
118 ER+, 70 ER American N/A c.975C→G G 
associated with 
family history of 
breast cancer, P 
= 0.0005
Iwase [43] Cases only (case-
control)
c.975C→G 13 ER/PR+, 57/30 British Increased risk with 
c.975C→G G, P 
= 0.057
Southey [49] Case-control c.975C→G 388/294 Australian early-
onset (<40 years)
None c.975C→G GG v. 
CC, OR 1.59 
(95% CI 0.7–3.6)
Schubert [48] Familial cases, case-
control
c.975C→G, 
c.729C→T
31+139 familial, 
105/151
Caucasian-
American and 
African-American
c.975C→G: No 
increased risk for 
familial disease
28% G in relatives 
with breast 
cancer and 24% 
in unaffected 
relatives, P = 0.18
Curran [30] Cross-sectional 
association
c.975C→G 125/125 Caucasian-
Australian
None 83% c.975C→G C 
in cases v. 77% in 
controls, P = 0.14
Vasconcelos [44] Case-control c.975C→G 70/69 Portuguese Increased risk with 
c.975C→G G or 
GG, OR 2.3 
(1.10–5.1)
Fewer lymph node 
metastases with 
c.975C→G G or 
GG, P = 0.038
Kang [57] Case-control c.975C→G 110/45 Korean None More often ER+, 
PR+ and p53 – 
with c.975C→G 
G allele
Comings [50] Case-control c.454-351A→G 67/145 Mixed American Did not contribute 
to breast cancer 
variance in a multi-
gene model
Shin [42] Case-control c.454-397C→T, 
c.454-351A→G
205/205 Korean Decreased risk with 
c.454-351A→G 
A allele 0.4 (0.3–
0.6)
Association 
stronger among 
postmenopausal
Cai [45] Case-control c.454-397C→T, 
c.454-351A→G
1069/1166 Shanghai Chinese Increased risk with 
c.454-397C→T, 
TC OR 1.3 (1.0–
1.7) and CC OR 
1.4 (1.1–1.8)
Ranges in parentheses are 95% confidence intervals. ER/PR+/-, oestrogen receptor/progesterone receptor positive/negative; FH, family history; N/
A, not applicable; OR, odds ratio.Available online http://breast-cancer-research.com/content/6/4/R437
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(Table 1). There is nevertheless an established positive
association between breast cancer risk and bone mineral
density (BMD) [2], which in turn seems to be influenced by
ESR1 variation [3-5]. Hence, a role of ESR1 polymorphism
in the aetiology of breast cancer seems biologically plausi-
ble, although it might have been overlooked in earlier stud-
ies because of small sample size (Table 1). We have
genotyped five ESR1 variants in a large, population-based
case-control study; a dinucleotide repeat (TAn) polymor-
phism (microsatellite) in the promoter region, two single-
nucleotide polymorphisms (SNPs) in intron 1 (c.454-397C
→ T and c.454-351A → G, also known as PvuII or IVS1-
401 and XbaI or IVS1-354, respectively), and one silent
SNP each in exon 3 (c.729C → T) and exon 4 (c.975C →
G). We estimated the overall influence of ESR1 genotypes
and haplotypes in histopathological subgroups, and
according to oestrogen-related breast cancer risk factors,
on breast cancer risk.
Methods
Parent study
This nationwide population-based case-control study
encompassed all incident cases of primary invasive breast
cancer among women 50 to 74 years of age resident in
Sweden between October 1993 and March 1995, as pre-
viously described in detail [6]. Cases of breast cancer in
situ were not included. Breast cancer patients were identi-
fied at diagnosis through the six Swedish regional cancer
registries, to which the reporting of all malignant tumors is
mandatory. All Swedish residents are assigned a unique
national registration number. This number is recorded in all
registries, including the Total Population Register. It is pos-
sible for researchers, provided that the appropriate permis-
sions are granted, to approach the authority in charge of
the Total Population Register (currently the Tax Authority)
and ask for the national registration numbers and
addresses of people that fulfil certain criteria specified by
the researcher. Control women were randomly selected
from the general population according to the expected age
frequency distribution (in 5-year age groups) of cases.
Cases were asked to participate in the study by their
respective physicians. When patients consented, they
received a mailed questionnaire asking for detailed informa-
tion about intake of menopausal hormones and oral contra-
ceptives, weight, height, reproductive history, medical
history, and other lifestyle factors. Controls were contacted
directly with the questionnaire. Eighty-four percent of eligi-
ble cases (n = 3345) and 82% of the controls (n = 3454)
ultimately participated in the parent study. Among the par-
ticipating controls, 455 who failed to return the mailed
questionnaire were interviewed by phone. Results from the
parent study are available in previous publications [6-8].
Selection of present study population
We randomly selected 1500 women with invasive breast
cancer and 1500 controls (frequency-matched by age)
among postmenopausal participants without any previous
malignancy (except in situ cervix carcinoma or non-
melanoma skin cancer) in the parent study. To increase sta-
tistical power in subgroup analyses, we additionally
selected all remaining eligible cases and controls who had
taken menopausal hormone treatment (either medium-
potency oestrogen treatment only or medium-potency oes-
trogen in combination with progestin) for at least 4 years
(191 cases and 108 controls) and all women with self-
reported diabetes mellitus (110 cases and 104 controls).
In total, 1801 cases and 1712 controls were selected. In
addition, 345 controls from the parent study selected for a
parallel endometrial cancer study who fulfilled the inclusion
criteria could be added to our sample of breast cancer-free
controls. The present study was approved by the respec-
tive Institutional Review Boards at Karolinska Institutet and
Uppsala University and was performed in compliance with
the Helsinki Declaration.
Collection of biological samples
We contacted all selected living women by mail, and those
who gave informed consent received a blood sampling kit
by mail. Whole blood samples were drawn at a primary
health care facility close to the woman's home. Breast can-
cer cases who declined to donate a blood sample were
asked to authorise our use of archived paraffin-embedded
tissue taken at breast cancer surgery. We also attempted
to retrieve archived tissue samples from all deceased
breast cancer cases. We obtained blood samples from
1322 and archived tissue samples for 247 breast cancer
patients (87% of all selected). Among the chosen control
women, 1524 (74%) contributed blood samples. Reasons
for non-participation included lack of interest in or scepti-
cism about genetic research, old age and, in some
instances, severe disease or death. We thus obtained final
population-based participation rates of 73% in cases and
61% in controls.
We isolated DNA from 3 ml of whole blood with the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI) in
accordance with the manufacturer's instructions. From
non-malignant cells in paraffin-embedded tissue we
extracted DNA by using a standard phenol/chloroform
nnmsdzz protocol [9].
Genetic analyses
SNPs and microsatellite markers
We selected the ESR1 polymorphisms to be analyzed from
the literature [10-13]. All primers and probes for the 5' pro-
moter TA-repeat at – 1174 base pairs upstream of exon 1
[HGVbase STR000063453], the intron 1 SNPs c.454-
397C  → T (previously known as PvuII or IVS1-401,Breast Cancer Research    Vol 6 No 4    Wedrén et al.
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[dbSNP rs2234693]) and c.454-351A → G (previously
known as XbaI or IVS1-354, [dbSNP rs9340799]), and the
exonic c.729C → T (codon 243 CGC → CGT, synony-
mous Arg, [dbSNP rs4986934]) and c.975C → G SNPs
(codon 325 CCC → CCG, synonymous Pro, [dbSNP
rs1801132]) were designed on the basis of the reference
sequences [GenBank AF082876], [GenBank AF326912]
and [GenBank NM_000125], respectively. For the fluores-
cence polarisation and minisequencing assays [14], we
designed minisequencing primers complementary to the
sequence immediately adjacent to the SNPs. For the
Molecular Beacon assay [15], we designed two fluores-
cently labelled allele-specific probes for each SNP, carry-
ing the variable position in the middle of the loop region
[16]. We used a web-based DNA folding program (mfold)
[17] to estimate the stability of the stem and loop structure
of the Molecular Beacon probes. A full description of the
laboratory protocol and also the primer and probe
sequences and their modifications are given in Additional
file 1.
Minisequencing assay with fluorescence polarisation 
detection
The region containing the intron 1 SNPs, c.454-397C → T
and c.454-351A → G, was amplified in one polymerase
chain reaction (PCR) fragment from 20 ng of genomic
DNA. The PCR products were treated enzymatically to
remove remaining primers and nucleotides, and the minise-
quencing reactions were performed with the two dideoxy-
nucleotides relevant for the particular SNP fluorescently
labelled and included at a 1:5 ratio relative to unlabelled
dideoxynucleotides. The fluorescence signals were read on
an Analyst AD™ (Molecular Devices Corporation, Sunny-
vale, CA); genotypes were assigned by the software sup-
plied with the instrument, and a custom-made Excel macro.
In each run, positive controls for the three genotypes and
negative controls were included. Both DNA polarities were
analysed and the results were concordant in all samples.
About 30% of the assays were repeated; the results were
identical. In addition, 3% of the genotypes were validated
by solid-phase minisequencing.
Molecular Beacon assay
To analyse the exonic SNPs c.729C → T and c.975C →
G, 10 ng of genomic DNA was amplified with real-time
PCR monitoring of fluorescence signals with an ABI Prism
7700 Sequence Detection System (Applied Biosystems).
The increase in fluorescent signal was registered during
the annealing step of the reaction, and the end-point sig-
nals were used to assign the genotypes as previously
described [16]. In each run, positive controls for the three
genotypes and negative controls were included. Both pos-
sible nucleotides of the SNP were interrogated in the same
reaction. About 3% of the assays were repeated; the
results were identical. Two percent of the assays were val-
idated by solid-phase minisequencing. The Molecular Bea-
con assay has previously been quantitatively validated in
our laboratory [16].
Solid-phase minisequencing assay
Solid-phase minisequencing in microtitre plates [18] was
used in part to genotype the c.729C → T SNP. The assay
also served as a reference method for the other SNP
assays.
Microsatellite assay
The TA-repeat region was amplified, with one PCR primer
fluorescently labelled, using an ABI-877 Integrated Thermal
cycler PCR robot with standard reagents (Applied Biosys-
tems) [19]. The PCR products were separated by using a
96-well ABI 377 automatic sequenator and analysed with
software supplied with the instrument (all Applied Biosys-
tems). In each run, two or three negative controls were
included. About 1% of the assays were repeated; they gave
concordant results. After calculation of actual number of TA
repeats there was no difference between repeated runs of
the same sample. The assay was validated by control
sequencing of three different repeat lengths.
Statistical methods
We tested for Hardy–Weinberg equilibrium (HWE) among
cases and controls separately. We considered the data for
TAn in its original form, as eight categories, or dichotomised
into long and short (not more than 14 repeats or more than
14 repeats), because the TAn lengths were bimodally dis-
tributed with peaks at 11 and 18 repeats, with a dip at 14
repeats.
We also estimated all pairwise linkage disequilibrium val-
ues |D'| and r2 [20,21]. Although there are disadvantages
associated with r2 compared with |D'| for linkage disequilib-
rium mapping [22,23], r2 is arguably the most relevant
measure for association analysis, because there is a simple
inverse relationship between r2  and the sample size
required to detect association between susceptibility loci
and SNPs [21].
For association analyses, using single loci genotypes, we
used conditional logistic regression [24] to calculate odds
ratios (ORs) and 95% confidence intervals (CIs). We con-
ditioned on the variables used for selection, namely age in
5-year categories, long-term use of menopausal hormones,
and diabetes mellitus (see the section on Selection of
present study population above). We evaluated possible
associations between ESR1  polymorphisms and other
exposures/covariates by scrutinising 2 × k tables and cal-
culating χ2 statistics. Continuous variables were catego-
rised for this purpose. Where there seemed to be plausible
evidence of association, the exposure was considered
either a potential confounder or a factor in the causal path-Available online http://breast-cancer-research.com/content/6/4/R437
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way between ESR1 and breast cancer, and was tested as
such by introducing it into the logistic regression model.
We tested for disease–haplotype association by using like-
lihood-based approaches. We used the software EH plus
[25] as well as routines written in the S-PLUS (Insightful)
programming language. Most available software (including
EH plus) for testing association between haplotypes and
case/control status assume multiplicative penetrance; that
is, the OR comparing two haplotype copies against none is
assumed to be the square of the OR comparing one
against none. Under this assumption, together with the
assumption of HWE in the population and the assumption
of a rare disease, it can be shown that cases, as well as
controls, will be in HWE. This means that it is possible to
perform a likelihood ratio test by comparing a model that
infers haplotype phase for cases and controls separately
(both under HWE, with different haplotype frequencies)
with a model that infers haplotype phase for cases and con-
trols jointly (that is, under HWE, identical haplotype fre-
quencies). For the most part we have used this approach
(using EH plus). We have also written our own program to
estimate haplotype–case/control status association. The
method in this program is in essence identical to that used
by Stram and colleagues [26]. This makes use of sampling
fractions that are assumed to be known (in practice esti-
mated from population register data; our program requires
as input the ratio of sampling fractions between cases and
controls). With this ascertainment information we can in
principle estimate any model (we are not restricted to par-
ticular penetrance assumptions). For our program we con-
sider the likelihood pr(y|x,s = 1), where y is case/control
status, x represents covariate information and s is an indi-
cator variable for whether a subject is selected to the sam-
ple. We essentially adapt the approach of Neuhaus [27],
specifically to the situation in which there is missing covari-
ate information, in this case haplotype phase. The program
is able to estimate models other than multiplicative
penetrance and enables adjustment for other covariates.
Given that the present study is based on large age strata
we wished to adjust for this by including age group as a
covariate. A likelihood ratio test did not give evidence
against a model of multiplicative penetrance (we compared
the goodness of fit of the multiplicative penetrance model
to the goodness of fit of a model that specifies an individual
risk for each unique haplotype pair). Our program also rep-
resents a convenient framework within which to estimate
haplotype–environment interaction. Results reported here
for models involving haplotypes are based on our own
program.
We fit a variety of models of association between ESR1
variants and breast cancer risk. We chose to fit models
separately for lobular and ductal cases because there is an
indication in the literature that these two histotypes have
partly different aetiologies. For single-locus genotype
effects we opted to include a parameter for each genotype
(AA, Aa, aa) rather than test a battery of models with a
specified penetrance (dominant, recessive, multiplicative
penetrance/allele counting), which have one degree of
freedom less. For haplotype effects we fitted multiplicative
penetrance models (see above).
Because we fit several models we also make adjustments
for multiplicity. We use a permutation-based approach that
controls the family-wise error rate (probability of rejecting
one or more true null hypotheses of no association). This is
based on the permutation step-down procedure of Westfall
and Young [28], and takes into account the dependence
structure of the polymorphisms/hypotheses. The permuta-
tion approach to multiple testing is computationally
demanding, particularly when haplotype phase has to be
inferred, and for this reason we adjust only P values for the
ductal cases versus control group tests. This is reasonable
because the power of the individual tests for lobular cases
versus controls is weak; unlike Bonferroni procedures, for
the permutation approach that we use, a completely mean-
ingless test (power ≈ 0) does not affect the other tests at
all because it will never affect the distribution of the mini-
mum P-value statistic in the lower α tail. We additionally
remove the TA repeat, because of deviance from HWE
(see below), and c.729C → T, because of low rare-allele
frequency, when adjusting for multiplicity. This means that
we apply a multiplicity adjustment to P values from tests of
seven dependent hypotheses.
Results
General
We were able to genotype the SNPs in more than 99% of
the biological samples. We obtained complete information
in all five markers from 1512 cases and 1511 controls.
For those participating by means of a blood sample or by
means of a normal tissue sample, the mean time between
breast cancer diagnosis and enrolment in the present study
was 5.1 years (range 6.8–3.5 years) and 5.9 years (range
7.5–4.6 years), respectively. Breast cancer stage was
more advanced in those who participated by means of nor-
mal tissue samples; 58% of tissue samples were from
cases with stage 2 or more advanced stages, whereas the
corresponding number was 38% in cases who donated
blood (P < 0.0001). The mean age of those who donated
a blood sample was similar in cases and controls, whereas
those for whom we used tissue were on average 1.6 years
older. Non-participants were on average slightly older than
genotyped participants. There were no notable differences
or trends in genotype frequencies over quartiles of time
between breast cancer diagnosis and time of blood dona-
tion (data not shown); neither were there any differences in
genotype frequencies between those who donated a bloodBreast Cancer Research    Vol 6 No 4    Wedrén et al.
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sample and those for whom we used normal tissue (data
not shown). Further, there were no significant differences in
genotype frequencies over breast cancer stages at diagno-
sis. As expected, mean age at first birth and mean number
of births reflected known case-control differences but were
largely the same between participants and non-partici-
pants. The allele and genotype frequencies in our study
population were similar to what has previously been found
in Caucasian populations [11,29,30].
Among controls, we did not find any convincing associa-
tions between any of the studied ESR1 polymorphisms sin-
gly and height, body mass index (BMI), smoking, diabetes
mellitus, age at menarche, age at first full-term birth, parity,
age at menopause, menopausal hormone use, weight gain
during adult life, alcohol intake, history of benign breast dis-
ease, first-degree family history, or use of oral contracep-
tives (data not shown).
Association with breast cancer
Single loci
There were no compelling overall relations between any of
the studied polymorphisms singly and breast cancer risk
(Table 2). If anything, there seemed to be a slight negative
association between homozygosity for any of the two intron
1 SNPs and heterozygosity for the c.975C → G SNP and
ductal cancer risk, but only one estimate was significant.
The association patterns between single loci genotype and
lobular cancer risk differed somewhat from those regarding
ductal cancer risk, but the lack of power precluded a con-
clusive comparison. In secondary analyses, we tested dif-
ferent cut-points for the TAn but found that no choice of cut-
point would have resulted in a significant association
between this marker and breast cancer risk.
Haplotypes
Haplotypes describe the genetic make-up more thoroughly
than SNPs. Thus, our further analyses of the association
between ESR1 polymorphism and breast cancer develop-
Table 2
Odds ratios for ductal and lobular breast cancer in relation to single locus genotype
Genotypea 00 01 11 PHWE
c
Polymorphism Cases/
Controls
ORb 95% CI Cases/
Controls
ORb 95% CI Cases/
Controls
ORb 95% CI
Promoter TAn
Ductal 369/445 1 Ref 494/593 1.01 0.84–1.21 230/312 0.87 0.70–1.09 <0.001, <0.0001d
Lobular 52/445 1 Ref 81/593 1.30 0.88–1.91 33/212 0.92 0.57–1.49
Intron 1 c.454-
397C→T
Ductal 347/384 1 Ref 542/651 0.93 0.77–1.12 229/313 0.80 0.64–1.01 0.32
Lobular 43/384 1 Ref 92/651 1.42 0.95–2.11 39/313 1.18 0.73–1.90
Intron 1 c.454-
351A→G
Ductal 522/577 1 Ref 471/610 0.86 0.72–1.02 124/161 0.86 0.66–1.12 0.88
Lobular 66/577 1 Ref 89/610 1.36 0.96–1.92 19/161 1.05 0.60–1.84
Exon 3 c.729C→T
Ductal 1037/
1253
1 Ref 84/93 1.07 0.78–1.45 1/3 0.41 0.04–4.00 0.20
Lobular 164/1253 1 Ref 10/93 0.92 0.46–1.83 0/3 - -
Exon 4 c.975C→G
Ductal 722/805 1 Ref 346/477 0.81 0.68–0.96 54/67 0.93 0.64–1.35 0.87
Lobular 106/805 1 Ref 59/477 0.94 0.66–1.34 9/67 1.00 0.48–2.10
OR, odds ratio. aThe genotypes are as follows: TAn, 00 ≤ 14/≤ 14, 01 ≤ 14/>14, 11 >14/>14; c.454-397C → T, 00 T/T, 01 T/C, 11 C/C; c.454-
351A → G, 00 A/A, 01 A/G, 11 G/G; c.729C → T, 00 C/C, 01 C/T, 11 T/T; c.975C → G, 00 C/C, 01 C/G, 11 G/G. bLong-term users of 
menopausal hormones and diabetics were oversampled; thus, logistic regression models are adjusted for age and sampling category, which 
means that only those with complete information about hormone use and diabetes mellitus were included. cP value for χ2 test of deviation from the 
assumption of Hardy–Weinberg equilibrium, among controls only. dFor this test for deviation from Hardy–Weinberg equilibrium either all 
microsatellite alleles were considered or lengths were categorised into ≤10, 11, 12 or 13, 14–16, 17, 18, 19, or ≥ 20.Available online http://breast-cancer-research.com/content/6/4/R437
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ment, overall and stratified according to hormonal factors,
are confined to the influence of different haplotypes.
There is no evidence of extensive historical recombination
between the typed SNPs (pairwise |D'| values 0.998,
0.872, 0.848; Table 3). However, r2 values indicate that the
allelic association is not strong.
Table 4 shows the estimated haplotype frequencies based
on the c.454-397C → T, c.454-351A → G, c.729C → T
and c.975C → G SNPs. Of the controls, 65% carried
either of the two most common haplotypes. Out of 16 pos-
sible haplotypes, only 6 were represented among more
than 98% of the women in our study. Although the
genotype frequencies of the four SNPs were in accordance
with HWE, the genotype frequency of the TAn was not, nei-
ther when all alleles were considered nor when the repeat
lengths were categorised (P  < 0.0001). We therefore
excluded the TAn marker from haplotype reconstruction
because it did not fulfil the necessary assumptions. Further-
more, the c.729C → T marker was expelled from further
haplotype analyses, because the minimal prevalence of the
rare allele would not allow meaningful inference.
In Table 5 we present P values, unadjusted and adjusted
for multiple comparisons, for the main effects tested, begin-
ning with single-locus associations. Next we explored the
prevalence of three two-locus haplotypes among cancer
cases versus controls (Table 5). We found an association
between ESR1 and ductal, but not lobular, cancer risk in a
haplotype analysis based on the c.975C → G marker in
combination with either c.454-397C → T or c.454-351A
→ G (Table 5). Likelihood-ratio tests evaluating models in
which each haplotype carries its own risk (that is, a variable
with four categories) were statistically significant (P  =
0.019 and 0.022, respectively; df = 3). The corresponding
P values adjusted for multiple comparisons were 0.07 and
0.08, respectively.
The three-SNP haplotype composed of the c.454-397C →
T, c.454-351A → G and c.975C → G SNPs was not more
strongly associated with breast cancer risk than any of the
Table 3
Pairwise linkage between polymorphisms in the oestrogen receptor α
|D|
r2 TAn
a c.454-397C→T c.454-351A→Gc . 7 2 9 C →T c.975C→G
TAn
a - 0.784 0.727 0.122 0.161
c.454-397C→T 0.569 - 0.998 0.895 0.329
c.454-351A→G 0.337 0.587 - 0.872 0.242
c.729C→T 0.001 0.028 0.016 - 0.848
c.975C→G 0.006 0.029 0.009 0.097 -
aFor |D'| TAn repeat lengths were divided into eight categories, ≤10, 11, 12 or 13, 14–16, 17, 18, 19, or >20. This ensured that there were few 
cells that contained fewer than five observations. For r2 the TAn repeat is dichotomised. bAll |D'| values are statistically significant at α = 0.001.
Table 4
Distribution of ESR1 four-locus haplotype frequencies as estimated through expectation-maximisation algorithms
Locus Proportion
c.454-397C→T c.454-351A→Gc . 7 2 9 C →Tc . 9 7 5 C →GC o n t r o l s  ( n = 1511) Ductal cases (n = 1148) Lobular cases (n = 184)
T A C C 0.369 0.404 0.373
C G C C 0.285 0.267 0.276
C A C C 0.114 0.117 0.125
T A C G 0.123 0.117 0.123
C G C G 0.058 0.049 0.076
T A T G 0.032 0.027 0.021
Proportion accounted for by the above most common haplotypes: 0.981 0.981 0.994Breast Cancer Research    Vol 6 No 4    Wedrén et al.
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two-SNP haplotypes based on the c.975C → G marker in
combination with either c.454-397C → T or c.454-351A
→ G (Table 5).
Table 6 accounts for the age-adjusted relative risk, overall
and stratified according to breast cancer risk factors, for
ductal breast cancer in relation to the c.454-351A → G or
c.454-397C → T and c.975C → G haplotypes (AC and
TC, respectively). Under a model of multiplicative pene-
trance, the OR for carrying two copies of the haplotype
compared with none is the square of the estimates for car-
rying one copy of the haplotype compared with carrying no
copy. To save space we present only the latter estimates.
The OR for carrying one copy of the AC haplotype was
1.19 (95% CI 1.06–1.33) compared with carrying no copy.
The association was confined to overweight women (BMI
> 25) and seemed more pronounced among those with a
BMI of more than 28 kg/m2. There was a similar pattern of
risk for the TC haplotype. Further stratification revealed an
even stronger relation; when considering only women with
BMI > 30 with one AC compared with none, we found an
OR of 1.48 (95% CI 1.08–2.03) and among those with
BMI > 32 an OR of 1.60 (95% CI 1.02–2.49). The corre-
sponding ORs for the TC haplotype were 1.59 (95% CI
1.15–2.21) for BMI > 30 and 1.71 (95% CI 1.08–2.70) for
BMI > 32. The effect of the AC or TC haplotype was more
pronounced in uniparous women but there was no trend
over number of pregnancies. There were no indications of
interaction between AC or TC haplotype and menopausal
hormone use, family history, years of menstruation or age at
menopause.
The AC haplotype seemed to be more common in controls
with low BMI (Table 6). A test of association between BMI
in two categories (less than 28 and 28 or more) and AC
haplotype versus the other three possible haplotypes
yielded P = 0.09. There was no association between BMI
and TC haplotype (P = 0.48). In a model with BMI in two
categories the P value for interaction between haplotype
and BMI was 0.12 for the AC and 0.047 for the TC
haplotype.
Discussion
Our results indicate that natural allelic variation in ESR1
might be associated with postmenopausal ductal breast
cancer risk; common haplotypes, composed of weakly
linked markers, were in our data associated with increased
breast cancer risk. The associations seemed the most pro-
nounced in groups with high BMI.
Our study has strengths in that it is population-based,
large, and set in a comparatively homogenous population
with regard to ethnicity and menopausal status. In addition,
we had some possibility of evaluating potential interaction
with other breast cancer risk factors.
To our knowledge, no previous study has considered the
influence of three-marker haplotypes in ESR1 on breast can-
cer risk. Two of the loci studied are in untranslated regions,
and one locus is a base-pair exchange in the third codon
position that does not alter the resulting amino acid. The pol-
ymorphisms could theoretically have direct regulatory roles
(see below) but can also be regarded as markers, potentially
in linkage disequilibrium with a functional locus or loci.
Table 5
P values from single genotype and haplotype association tests
SNP/haplotype tested Unadjusted Adjusted for multiple testing dfa
Control v. ductal Control v. lobular Control v. ductal
Single loci
c.454-397C→T 0.154 0.458 0.157 2
c.454-351A→G 0.128 0.292 0.235 2
c.729C→T 0.524 0.440 -b 2
c.975C→G 0.037 0.845 0.106 2
Two-locus haplotypes
c.454-397C→T and c.454-351A→G 0.152 0.918 0.219 3
c.454-397C→T and c.975C→G 0.019 0.921 0.071 3
c.454-351A→G and c.975C→G 0.022 0.930 0.077 3
Three-locus haplotype
c.454-397C→T and c.454-351A→G and c.975C→G 0.097 0.995 0.178 7
aDegrees of freedom. Genotype and haplotype frequency distributions are compared between cases and controls without prior assumptions 
about high-risk or low-risk genotypes or haplotypes. bExcluded from adjustments for multiple testing because of low allele frequency (see the text).Available online http://breast-cancer-research.com/content/6/4/R437
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If the underlying model for the disease is that combinations
of SNP alleles are causally important, it is essential to
define haplotypes and to use them as the unit of exposure
in the analysis. A possible explanation for the observed
association, apart from its being a chance finding, is that
there is such a functional combination of SNP alleles; that
is, that the two markers (or loci linked to the markers) in
combination alter the function of the gene, such as RNA
stability or the translation machinery [31]. Functional com-
binations of SNP alleles composed of polymorphisms in
non-coding regions have been shown to exist [32].
If in contrast it seems likely that there is only one disease
locus, haplotypes are useful in that they can help to make
the study of a gene more efficient through reducing the
number of SNPs that need to be typed in the entire study
population. This can be accomplished by making use of the
linkage disequilibrium between markers in a gene and
selecting for subsequent typing the SNPs that best capture
the haplotype structure of a gene, the so-called haplotype
tagging SNPs.
Our four SNP markers and one dinucleotide repeat were
not specifically selected to define ESR1  haplotypes.
Rather, they were chosen because they were known to be
polymorphic at the time when the study was planned.
Clearly, the ability to capture the gene's haplotype diversity
is limited by the use of only four markers, of which only three
exist with a substantial prevalence. Our design is not opti-
mal in the light of current knowledge. It would be more unbi-
ased to address the problem by using strategies in which a
comprehensive set of SNPs are identified and validated
and subsequently a smaller set are chosen specifically to
tag the important haplotypes in the gene. Our intention
here was merely to make the best possible use of data that
were already available.
Table 6
Ductal breast cancer risk in relation to high-risk haplotypes, stratified by breast cancer risk factors
Factor Number, cases/
controls
c.454-351A→G c.975C→G AC haplotype c.454-397C→T c.975C→G TC haplotype
Haplotype proportion, 
cases/controls
OR (95% CI)a, 1 v. 0 
copiesb
Haplotype proportion, 
cases/controls
OR (95% CI)a, 1 v. 0 
copiesb
All ductal cancer 
cases
1148/1511 0.531/0.484 1.19 (1.06–1.33) 0.412/0.373 1.19 (1.06–1.34)
BMI
<25 549/761 0.525/0.517 1.04 (0.89–1.23) 0.404/0.388 1.08 (0.91–1.27)
25-<28 299/429 0.531/0.458 1.32 (1.06–1.64) 0.391/0.348 1.21 (0.97–1.51)
≥ 28 300/321 0.541/0.456 1.41 (1.12–1.77) 0.449/0.357 1.48 (1.17–1.88)
Parity
0 158/134 0.495/0.472 1.14 (0.82–1.60) 0.399/0.388 1.11 (0.80–1.54)
1 248/258 0.535/0.439 1.43 (1.10–1.84) 0.422/0.349 1.35 (1.04–1.74)
2+ 706/1043 0.535/0.496 1.17 (1.01–1.34) 0.413/0.377 1.17 (1.02–1.35)
Menopausal hormone 
treatment
<2 years 861/1169 0.533/0.482 1.23 (1.08–1.40) 0.416/0.374 1.21 (1.06–1.38)
≥ 2 years 251/266 0.515/0.490 1.08 (0.84–1.40) 0.391/0.369 1.08 (0.84–1.40)
Family history
No 935/1246 0.528/0.486 1.18 (1.04–1.33) 0.413/0.368 1.21 (1.07–1.30)
Yes 183/128 0.548/0.505 1.17 (0.84–1.63) 0.403/0.425 0.93 (0.67–1.30)
Age at menopause
≤ 49 years 324/506 0.555/0.496 1.25 (1.02–1.54) 0.431/0.385 1.25 (1.01–1.54)
49.5–51.5 years 445/503 0.511/0.470 1.19 (0.98–1.43) 0.397/0.356 1.19 (0.98–1.45)
≥ 52 years 372/489 0.534/0.494 1.18 (0.97–1.44) 0.411/0.372 1.17 (0.96–1.44)
BMI, body mass index. aAge-adjusted odds ratio and 95% confidence interval. bThe odds ratios (ORs) and CIs for two copies versus none are not 
shown because under a model of multiplicative penetrance the OR for two copies versus none is the square of the OR for one copy versus none.Breast Cancer Research    Vol 6 No 4    Wedrén et al.
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A weakness in our study is that, despite its size, we had
only a limited potential to investigate possible interactions
between haplotype and other breast cancer risk factors.
Because it is plausible that moderate genetic effects are
manifested only in the presence of other exposures, it is
highly desirable to be able to perform analyses of
interaction.
The error of haplotype frequency estimation by the expec-
tation-maximisation (EM) algorithm has been shown by to
be low under various conditions with regard to, for example,
heterozygosity, haplotype frequency distributions, and link-
age disequilibrium [33]. Haplotype frequency estimation
with EM algorithms entails assuming that the single marker
genotype frequencies are in HWE. This assumption is eas-
ily testable. In this study we could not establish HWE for
the TAn among controls; this polymorphism was therefore
not included in haplotype reconstruction. The reason for
deviation of the TAn from HWE is unclear. If the reason for
the deviation, contrary to our belief, were due to genotyping
error and if the error were random with regard to case-con-
trol status, association between the TAn and breast cancer
would be underestimated.
Another supposition used for our disease–haplotype asso-
ciation estimation is a model of multiplicative penetrance.
Multiplicative penetrance, rather than dominant, is likely in
the action of common genetic variants because their effect
is thought to be modest. If instead a recessive model were
correct, our estimates would be conservative. In our data, a
model of multiplicative penetrance could not be rejected.
Selection bias is a potential problem in case-control stud-
ies, and our participation rates, calculated by using those
eligible for the parent study in the denominator (73% and
61% in cases and controls, respectively), could lead to
spurious findings but only if participation were related to
genotype or haplotype. Survivor bias might be a concern in
our study because death and severe disease were reasons
for non-participation. If a genetic variant is associated with
severe breast cancer but not with less severe breast can-
cer, and if the more severe cases of breast cancer are less
likely to participate because they have died, any association
with breast cancer overall would be biased towards the
null. One can also view this as an issue of generalisability;
in other words, our findings do not pertain to more aggres-
sive breast cancer. However, in our data genotype frequen-
cies did not vary according to time between diagnosis and
enrolment through blood versus tissue donation (the latter
mainly representing deceased cases). Neither were geno-
type associations appreciably different across stages at
breast cancer diagnosis. We therefore conclude that survi-
vor bias is not a major problem in our study.
Some observations make functional consequences of
some of the five studied ESR1 polymorphisms plausible.
The TAn microsatellite is located in the promoter region
and, as directly exemplified by Enattah and colleagues [34]
in a study about lactose intolerance, promoter variants can
severely affect gene function. Herrington and colleagues
[35] found that the IVS-401 C allele contains a potential
binding site for Myb transcription factors and showed that
this can augment transcription up to 10-fold. In general, our
knowledge about the functional significance of non-coding
DNA sequences is not fully formed, but there is evidence
that upstream, downstream and intronic sequences have
important regulatory roles [36].
There are some reports that suggest connections between
ESR1 variants and breast cancer risk factors. Ushiroyama
and colleagues found that Japanese women with the
c.454-397C → T CT genotype had higher plasma and
serum oestradiol levels than those with the TT genotype
[37]. In a Dutch population, c.454-397C → T TT was asso-
ciated with an earlier onset of menopause, which would
entail a decreased risk for breast cancer [38]. In contrast,
Deng and colleagues [39] found c.454-397C → T TT to be
associated with higher BMI and against a tendency to gain
weight with age, characteristics previously shown to be
associated with an increased risk for breast cancer. These
associations between the c.454-397C → T variant and
onset of menopause, BMI, and weight gain were not cor-
roborated by our data. However, we did find a tentative
association between BMI and a haplotype constructed by
the c.454-351A → G SNP and the c.975C → G SNP. In a
previous study about endometrial cancer, a disease closely
related to oestrogen exposure, we found that the c.454-
397C → T CC and c.454-351A → G GG genotypes were
associated with a decreased risk for endometrial cancer
[40].
The previous literature of ESR1 polymorphism in relation to
breast cancer risk is inconclusive (Table 1). In contrast to
our findings, one study showed an increased risk with
c.454-351A → G G allele [41] or decreased risk with the
c.454-351A  → G A allele [42], others showed an
increased risk with the c.975C → G G allele [43,44]. In a
recent large Chinese study [45] the c.454-397C → T C
allele was associated with an increased breast cancer risk,
which is contrary to the tendencies in our data for ductal
cancers but in line with those for lobular cancers. Histo-
types were not reported in the Chinese study but the major-
ity were most probably ductal cancers. The remaining
investigators did not find any association with breast can-
cer risk [11,13,30,46-50].
BMI is the most important determinant of oestrogen levels
in postmenopausal women. Our finding that the association
grew stronger as we considered women with increasingAvailable online http://breast-cancer-research.com/content/6/4/R437
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BMI is biologically plausible and would, if it is real, indicate
that ESR1 variation is more influential in the presence of
higher levels of oestrogen. Contradicting this theory,
however, is the fact that we could not see any correspond-
ing influence of duration of menopausal hormone
treatment.
The association between BMD and ESR1 polymorphism is
by far the most closely investigated, in particular with
regard to the intron 1 SNPs. Any variant in ESR1  that
seems to increase bone mass or to decrease risk for oste-
oporosis and fractures would be expected to increase
breast cancer risk because it might indicate a greater influ-
ence of oestrogen. However, the results of studies of BMD
and ESR1 polymorphism are conflicting. Among the largest
studies, some have shown, in line with the suggestions in
our data, that the c.454-397C → T T allele or TT genotype
confers the highest BMD, that is, the strongest oestrogenic
influence [3,51], whereas others found the highest BMD in
those with the C allele or CC genotype [52]. Similarly, for
the c.454-351A → G locus, although some, supported by
our findings, found the A variant to be associated with
higher BMD [3,51,53], others found high BMD with the G
variant [54].
The quest for disease-causing genes has grown markedly
over the years. Nevertheless, the efforts have yielded few
lucid results. It is likely that the genetic alterations we are
looking for are of low penetrance and thus implicitly need
co-action or interaction with other exposures to show
strong associations. Another plausible scenario is that
breast cancers arise from various genetically distinct causal
mechanisms, in other words that genetic heterogeneity is
present, which acts to blur the gene–disease associations
under study. Population history might also contribute to an
explanation of previous diverging results in different popu-
lations such that the causative variant might be linked to
one marker allele in one population but with the other allele
in another population. A contributing fact is that many stud-
ies have lacked sufficient power to capture such biological
complexity either because of small sample size or, as has
been argued by some, because of inappropriate study
design [55].
When initiating this study we had strong belief in the pos-
sibility of ESR1 variation's being involved in breast carcino-
genesis; there is undisputed evidence of oestrogens'
causal role in breast carcinogenesis, and oestrogenic
action is mediated through oestrogen receptor α. Further-
more, there were existing data indicating that certain ESR1
variants are associated with oestrogenic action.
Wacholder and colleagues [56] suggest making use of
prior belief in a genetic variant when trying to determine
whether a statistically significant finding is noteworthy.
They recommend calculating the false positive report prob-
ability (FPRP) by using the power of the study to detect the
particular finding, the P value for the association, and the
prior belief. Our prior estimate was that the chance of asso-
ciation between ESR1  and breast cancer was at least
10%. The power for detecting an odds ratio of 1.19 for the
AC haplotype at an α level of 0.05 in our sample was 0.79
when we compared the AC with the next most common
haplotype (AC being the most common). P for the associa-
tion was 0.02. With our own prior of 0.1 the FPRP was
0.18, which makes our finding noteworthy. However, many
previous studies have failed to establish a role for ESR1 in
breast carcinogenesis, which decreases our priors. Yet,
because most previous studies were small and because no
other study has considered haplotypes between the SNPs
in intron 1 and exon 4 the influence on the prior would not
be large. Nevertheless, our design might not have captured
the full haplotype diversity of ESR1. The belief in haplo-
types based on the few markers that we have chosen is
clearly lower. If, say, prior belief is then 0.01, the FPRP
becomes a substantial 0.71.
Conclusions
We found suggestions of an association between ESR1
haplotypes and the risk for postmenopausal ductal breast
cancer of mild to moderate severity, although this is
conceivably a false positive finding. This association
seemed stronger as we considered women with higher
BMI. If these haplotypes truly entail an increased breast
cancer risk, owing to their high population prevalence, they
have the potential for substantial role in breast cancer aeti-
ology overall.
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